Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.

Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.

Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Abstract: A method of making a graft copolymer, comprising the steps of obtaining a first polymer comprising at least one carbon-carbon double bond, the first polymer derived from at least one first monomer, the at least one first monomer comprising a conjugated diene monomer; obtaining a second polymer, the second polymer capable of exhibiting a lower critical solution temperature (LCST) and comprising a terminal functional group capable of reacting with the carbon-carbon double bond; and reacting the second polymer with the first polymer to form a graft copolymer, the graft copolymer comprising a backbone derived from the first polymer and sidechains derived from the second polymer.

Abstract: The present invention is directed to a copolymer comprising: a polymeric backbone chain derived from a monomer comprising at least one conjugated diene monomer and optionally at least one vinyl aromatic monomer; and polymeric sidechains bonded to the backbone chain, the sidechains comprising a polymer capable of exhibiting a lower critical solution temperature (LCST).

Abstract: The present invention is directed to a polymer blend, the blend including a diene-based elastomer grafted with a substituted acrylamide polymer through a sulfur atom, and from 1 to 20 percent by weight of an additional polymer miscible with the substituted acrylamide polymer.

Abstract: The present application describes a novel, advantageous purification method which guarantees the embryonation capability and the viability of a worm egg suspension. The T. suis worm eggs are first treated in a non-embryonated condition in a sulfuric acid solution at about =ph 2. Bacteria and viruses are thereby killed successfully. The germination number of yeasts and fungi is reduced. In a second step, the pH-value is increased and an orally tolerated preservative is added. Yeasts and fungi are thereby killed successfully. The suspension medium used in the second purification step can then be used as a culture medium for additional production (embryonation) and storage.

Abstract: A method for determining the biological activity of embryonated Trichuris eggs is described, in which at least one of the following determinations is carried out: a) Determination and/or confirmation of the stage of the embryonal development of helminth eggs with the aid of quantitative PCR analysis by using suitable marker sequences for ascertaining the copy number of the genomic DNA, b) Determination of the metabolic activity of embryonated helminth eggs by means of biochemical and/or molecular biological methods, c) Determination of the inducibility of gene expression in embryonated helminth eggs, d) Microscopic determination of the motility of helminth larvae in the egg over long periods of observation after pre-incubation at increased temperatures and/or e) Determination of the hatching rate of Trichuris larvae in a laboratory animal, wherein the intact embryonated eggs recovered from the contents of the intestine are quantified compared to an internal standard.

Abstract: The present invention is directed to a functionalized elastomer comprising: a polymeric backbone chain derived from a monomer comprising at least one conjugated diene monomer and optionally at least one vinyl aromatic monomer; and a functional group bonded to the backbone chain, the functional group comprising a multidentate ligand capable of complexing with a metal ion.

Abstract: The present invention is directed to a method of making a graft copolymer, comprising the steps of: obtaining a first polymer comprising at least one carbon-carbon double bond, the first polymer derived from at least one monomer, the at least one monomer comprising a conjugated diene monomer; polymerizing a second monomer in the presence of a thiocarbonylthio RAFT chain transfer agent to form a polymer comprising a terminal thiocarbonylthio group; cleaving the terminal thiocarbonylthio group to a thiol group to form the second polymer comprising a terminal thiol group; reacting the second polymer with the first polymer to form a graft copolymer, the graft copolymer comprising a backbone derived from the first polymer and sidechains derived from the second polymer.

Abstract: The present invention is directed to a polymer blend comprising a first polymer and a second polymer, the first polymer comprising: a polymeric backbone chain derived from a monomer comprising at least one conjugated diene monomer and optionally at least one vinyl aromatic monomer; and polymeric sidechains bonded to the backbone chain, the sidechains comprising a polymer immiscible with the backbone; the second polymer consisting of a polymer miscible with the polymeric sidechains.

Abstract: The invention relates to an effervescent tablet for preparing a mouth rinsing solution, wherein the effervescent tablet exhibits a high release rate of budesonide. A high availability of the active ingredient during use as a mouth rinsing solution on the inflamed mucosa of the upper digestive tract is thereby achieved. The advantage of the formulation according to the invention lies in the bioavailability comparable to oral forms of administration, which allows the formulation to be used safely over an extended period of time.

Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The inventions further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.

Abstract: The invention relates to an effervescent tablet for preparing a mouth rinsing solution, wherein the effervescent tablet exhibits a high release rate of budesonide. A high availability of the active ingredient during use as a mouth rinsing solution on the inflamed mucosa of the upper digestive tract is thereby achieved. The advantage of the formulation according to the invention lies in the bioavailability comparable to oral forms of administration, which allows the formulation to be used safely over an extended period of time.

Abstract: The present invention is directed to a functionalized elastomer comprising: a polymeric backbone chain derived from a monomer comprising at least one conjugated diene monomer and optionally at least one vinyl aromatic monomer; and a functional group bonded to the backbone chain, the functional group comprising an oligopeptide or modified oligopeptide.

Abstract: The present invention is directed to a method of making a graft copolymer, comprising the steps of: obtaining a first polymer comprising at least one carbon-carbon double bond, the first polymer derived from at least one monomer, the at least one monomer comprising a conjugated diene monomer; polymerizing a second monomer in the presence of a thiocarbonylthio RAFT chain transfer agent to form a polymer comprising a terminal thiocarbonylthio group; cleaving the terminal thiocarbonylthio group to a thiol group to form the second polymer comprising a terminal thiol group; reacting the second polymer with the first polymer to form a graft copolymer, the graft copolymer comprising a backbone derived from the first polymer and sidechains derived from the second polymer.

Abstract: The present invention is directed to a copolymer comprising: a polymeric backbone chain derived from a monomer comprising at least one conjugated diene monomer and optionally at least one vinyl aromatic monomer; and polymeric sidechains bonded to the backbone chain, the sidechains comprising a polymer capable of exhibiting a lower critical solution temperature (LCST).